SCHEMBL25213409

SCHEMBL25213409

Cc1ccc(S(=O)(=O)Oc2cc(OCc3ccccn3)c(C=O)c(OS(=O)(=O)c3ccc(C)cc3)c2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 6/20 0.46
AURKB Q96GD4 1/20 0.45
INCENP Q9NQS7 1/20 0.45
ALDH1A1 P00352 6/20 0.43
KDM4E B2RXH2 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MEN1 O00255 4/20 0.39
KMT2A Q03164 4/20 0.39
GAA P10253 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
LMNA P02545 3/20 0.39
MAPK1 P28482 1/20 0.39
GFER P55789 1/20 0.39
MAPT P10636 3/20 0.39
NPSR1 Q6W5P4 2/20 0.39
HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25217507 0.88 PTPN1 (0.41) ALDH1A1MEN1KMT2AGAACYP1A2
SCHEMBL25216897 0.86 KMT2A (0.37) SYKAURKBINCENPALDH1A1SMN1; SMN2
SCHEMBL25211445 0.84 LMNA (0.46) ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL25240280 0.84 SYK (0.42) SYKAURKBINCENPALDH1A1KDM4E
SCHEMBL25213830 0.83 SYK (0.46) SYKAURKBINCENPALDH1A1KDM4E
SCHEMBL25223415 0.81 MAOB (0.47) MEN1KMT2AGAAESR1ESR2
SCHEMBL29567873 0.80 GAA (0.49) SYKAURKBINCENPSMN1; SMN2MEN1
SCHEMBL28517030 0.80 GAA (0.49) SYKAURKBINCENPSMN1; SMN2MEN1
SCHEMBL30301749 0.79 PTPN1 (0.36) ALDH1A1MEN1KMT2AGAACYP1A2
SCHEMBL25255064 0.78 PTPN1 (0.45) ALDH1A1SMN1; SMN2MEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12552758-B2 Inhibitors of MLH1 and/or PMS2 for cancer treatment Neophore Limited (GB) 2026-02-17 US disclosed
US-20230183197-A1 INHIBITORS OF MLH1 AND/OR PMS2 FOR CANCER TREATMENT Neophore Limited (GB) 2023-06-15 US disclosed
US-20230183197-A1 INHIBITORS OF MLH1 AND/OR PMS2 FOR CANCER TREATMENT Neophore Limited (GB) 2023-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12552758-B2 Inhibitors of MLH1 and/or PMS2 for cancer treatment MSH2, PMS2, MSH6 SYK 4652/4885AURKB 1876/4885INCENP 2362/4885
US-20230183197-A1 INHIBITORS OF MLH1 AND/OR PMS2 FOR CANCER TREATMENT MSH2, PMS2, MSH6 SYK 4045/4885AURKB 864/4885INCENP 1248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.